Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 Ingestion Induces a Less Inflammatory Cytokine Profile and a Potentially Beneficial Shift in Gut Microbiota in Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
- 2015-04-24
- Journal of the American College of Nutrition 34(6)
- Samuel J. Spaiser
- T. Culpepper
- C. Nieves
- M. Ukhanova
- V. Mai
- S. Percival
- M. Christman
- B. Langkamp-Henken
- PubMed: 25909149
- DOI: 10.1080/07315724.2014.983249
Abstract
Objective: This study determined whether older adults who consumed a probiotic mixture would have a greater proportion of circulating CD4+ lymphocytes, altered cytokine production, and a shift in intestinal microbiota toward a healthier microbial community.
Methods: Participants (70 ± 1 years [mean ± SEM]; n = 32) consumed a probiotic (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM2) or a placebo twice daily for 3 weeks with a 5-week washout period between intervention periods. Blood and stools were collected before and after each intervention. The percentage of circulating CD4+ lymphocytes and ex vivo mitogen-stimulated cell cytokine production were measured. In stools, specific bacterial targets were quantified via quantitative polymerase chain reaction (qPCR) and community composition was determined via pyrosequencing.
Results: During the first period of the crossover the percentage of CD4+ cells decreased with the placebo (48% ± 3% to 31% ± 3%, p < 0.01) but did not change with the probiotic (44% ± 3% to 42% ± 3%) and log-transformed concentrations of interleukin-10 increased with the probiotic (1.7 ± 0.2 to 3.4 ± 0.2, p < 0.0001) but not the placebo (1.7 ± 0.2 to 2.1 ± 0.2). With the probiotic versus the placebo a higher percentage of participants had an increase in fecal bifidobacteria (48% versus 30%, p < 0.05) and lactic acid bacteria (55% versus 43%, p < 0.05) and a decrease in Escherichia coli (52% versus 27%, p < 0.05). Several bacterial groups matching Faeacalibactierium prausnitzii were more prevalent in stool samples with the probiotic versus placebo.
Conclusions: The probiotic maintained CD4+ lymphocytes and produced a less inflammatory cytokine profile possibly due to the changes in the microbial communities, which more closely resembled those reported in healthy younger populations.
Keywords: Bifidobacterium bifidum G9-1; Bifidobacterium longum MM-2; Lactobacillus gasseri KS-13; cytokines; gastrointestinal function; gut microbiota; immune function; inflammation; older adults; probiotics.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium bifidum G9-1 | Enhanced Interleukin-10 Production | Beneficial | Large |
Bifidobacterium bifidum G9-1 | Increased Fecal Bifidobacteria Levels | Beneficial | Moderate |
Bifidobacterium bifidum G9-1 | Increased Lactic Acid Bacteria Levels | Beneficial | Moderate |
Bifidobacterium bifidum G9-1 | Maintained CD4+ Lymphocyte Levels | Beneficial | Moderate |
Bifidobacterium bifidum G9-1 | Reduced Fecal Escherichia coli Levels | Beneficial | Moderate |
Bifidobacterium lactis/longum | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
Bifidobacterium lactis/longum | Increased Fecal Bifidobacteria Levels | Beneficial | Moderate |
Bifidobacterium lactis/longum | Increased Lactic Acid Bacteria Levels | Beneficial | Moderate |
Bifidobacterium lactis/longum | Maintained CD4+ Lymphocyte Levels | Beneficial | Moderate |
Bifidobacterium lactis/longum | Reduced Cecal Escherichia coli Levels | Beneficial | Moderate |
Bifidobacterium longum MM-2 | Increased Fecal Bifidobacteria | Beneficial | Moderate |
Bifidobacterium longum MM-2 | Increased Interleukin-10 Levels | Beneficial | Large |
Bifidobacterium longum MM-2 | Increased Lactic Acid Bacteria Levels | Beneficial | Moderate |
Bifidobacterium longum MM-2 | Maintained CD4+ Lymphocyte Levels | Beneficial | Moderate |
Bifidobacterium longum MM-2 | Reduced Escherichia Coli Levels | Beneficial | Moderate |
Lactobacillus gasseri KS-13 | Enhanced Interleukin-10 Production | Beneficial | Large |
Lactobacillus gasseri KS-13 | Increased Fecal Bifidobacteria Levels | Beneficial | Moderate |
Lactobacillus gasseri KS-13 | Increased Lactic Acid Bacteria Levels | Beneficial | Moderate |
Lactobacillus gasseri KS-13 | Maintained CD4+ Lymphocyte Levels | Beneficial | Moderate |
Lactobacillus gasseri KS-13 | Reduced Fecal Escherichia coli | Beneficial | Moderate |